Seeking Alpha·2025-10-24 12:15Core Insights - The article discusses the performance and outlook of Crispr Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA) in the context of the gene therapy sector, highlighting the impact of regulatory uncertainties and pricing concerns on gene therapy stocks [1]. Company Analysis - Crispr Therapeutics and Intellia Therapeutics are positioned within the biotechnology sector, focusing on gene therapy as a novel treatment approach [1]. - The author has a long position in Crispr Therapeutics, indicating a positive outlook on the company's stock performance [2]. Industry Context - The gene therapy industry is currently facing challenges related to regulatory environments and pricing strategies, which have affected stock performance [1]. - The author emphasizes the importance of assessing the potential of novel treatments in driving shareholder returns within the biotechnology and healthcare sectors [1].